About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Chapters
Books
News
Editorials
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Scientometrics
Impact Factor
Discipline Ranks
H-Index
G-Index
Articles
Citations
Article Citations
Citation Distribution
Search This Journal
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
exaly
›
Journals
›
Expert Opinion on Orphan Drugs
›
Top Articles
Expert Opinion on Orphan Drugs
Pharmacology
1.1
(top 14%)
Impact Factor
1.2
(top 14%)
extended IF
23
(top 15%)
H-Index
607
authors
747
papers
2.6K
citations
1.1K
citing journals
3.4K
citing authors
Most Cited Articles of Expert Opinion on Orphan Drugs
Title
Year
Citations
Orphan drugs and rare diseases: a scientometric review (2000 – 2014)
2014
105
PSEUDOXANTHOMA ELASTICUM: DIAGNOSTIC FEATURES, CLASSIFICATION, AND TREATMENT OPTIONS
2014
49
Pathogenesis, Emerging therapeutic targets and Treatment in Sialidosis
2015
41
Enzyme replacement therapy for treating mucopolysaccharidosis type IVA (Morquio A syndrome): effect and limitations
2015
38
Pathogenesis, Epidemiology, Diagnosis and Clinical Aspects of Smith-Lemli-Opitz Syndrome
2015
35
Diagnosis, prevalence, and screening of familial dilated cardiomyopathy
2015
35
Clinical Features, Genetics and Potential Therapeutic Approaches for Birt-Hogg-Dubé Syndrome
2015
35
Alveolar echinococcosis: evaluation of therapeutic strategies
2014
32
Machado Joseph disease: clinical and genetic aspects, and current treatment
2015
29
Gene Therapy for Duchenne muscular dystrophy
2015
29
Emerging therapies and therapeutic concepts for lysosomal storage diseases
2013
29
From mysteries to medicines: drug development for fibrodysplasia ossificans progressive
2013
28
New therapeutic targets in rare genetic skeletal diseases
2015
27
Hard targets for a second skeleton: therapeutic horizons for fibrodysplasia ossificans progressiva (FOP)
2017
27
Pathogenic mechanisms and the prospect of gene therapy for choroideremia
2015
26
The potential of utrophin modulators for the treatment of Duchenne muscular dystrophy
2018
26
Tissue Chips to aid drug development and modeling for rare diseases
2016
26
Genetics and prospective therapeutic targets for Sjögren-Larsson Syndrome
2016
25
Therapies of mucopolysaccharidosis IVA (Morquio A syndrome)
2013
24
Pharmacological therapeutics targeting the secondary defects and downstream pathology of Duchenne muscular dystrophy
2016
24
Galactosialidosis: historic aspects and overview of investigated and emerging treatment options
2017
23
Pathogenesis, diagnosis and therapeutic strategies in WHIM syndrome immunodeficiency
2017
23
Obstacles and future of gene therapy for hemophilia
2015
23
Gene therapy for the treatment of X-linked retinitis pigmentosa
2018
23
Translating HDAC inhibitors in Friedreich's ataxia
2016
23
0
1
2
next
How are inpact factors calculated?
The impact factor (IF) is calculated by counting citations from peer-reviewed journals only.
extended IF
also counts citations from books and conference papers. However, no patent, abstract, working papers, online documents, etc., are covered.
site/software ©
exaly
; All materials licenced under
CC by-SA
.